Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
24 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
23 sept. 2021 16h01 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
22 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
20 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
12 août 2021 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021
05 août 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
28 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
22 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade
17 juin 2021 08h00 HE
|
Onconova Therapeutics, Inc.
Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s...